Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Amla is extremely rich in vitamin C and tannins and is used as an antioxidant and adaptogen in Ayurvedic medicine. It is generally very safe. High doses may have mild anticoagulant effects. It may enhance the effects of antidiabetic drugs. Very safe at standard doses.
Biological and Chemical Classification
- Scientific Name
- Emblica officinalis
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Amla Fruit Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:25
Evidence Distribution
-
Observational / other LOW evidence YELLOWEmblica officinalis Fraction Mitigates Depression via PI3K-AKT Pathway: A Pharmacological Study. ↗Sen A et al.. Emblica officinalis Fraction Mitigates Depression via PI3K-AKT Pathway: A Pharmacological Study.. Chem Biodivers. 2026. PMID:41771814.PMID 41771814 ↗Journal Chem BiodiversYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41771814/
-
Observational / other LOW evidence YELLOWIn-silico identification of anti-cholera phytochemicals from Indian medicinal plants. ↗Rahman K et al.. In-silico identification of anti-cholera phytochemicals from Indian medicinal plants.. PLoS One. 2026. PMID:41628183.PMID 41628183 ↗Journal PLoS OneYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41628183/
-
Observational / other LOW evidence YELLOWImmunohistochemical and metabolomic analysis of Tibetan medicine triphala in response to pancreatic tissues of diabetic rats. ↗Li XY et al.. Immunohistochemical and metabolomic analysis of Tibetan medicine triphala in response to pancreatic tissues of diabetic rats.. J Asian Nat Prod Res. 2026. PMID:41492878.PMID 41492878 ↗Journal J Asian Nat Prod ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41492878/
-
Observational / other LOW evidence YELLOWPlant-mediated synthesis: Transforming traditional Bangladeshi medicinal plants into immunomodulatory nanoparticles for enhanced shrimp immunity and pathogen control. ↗Hossain MMM et al.. Plant-mediated synthesis: Transforming traditional Bangladeshi medicinal plants into immunomodulatory nanoparticles for enhanced shrimp immunity and pathogen control.. Microb Pathog. 2026. PMID:41177312.PMID 41177312 ↗Journal Microb PathogYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41177312/
-
Observational / other LOW evidence YELLOWThe Multifaceted Benefits of Triphala: Uncovering Phytochemical and Pharmacological Properties From Antiquity to Modern Times. ↗Thallada V et al.. The Multifaceted Benefits of Triphala: Uncovering Phytochemical and Pharmacological Properties From Antiquity to Modern Times.. Chem Biodivers. 2026. PMID:41151054.PMID 41151054 ↗Journal Chem BiodiversYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41151054/
-
Observational / other LOW evidence YELLOWComparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine. ↗Singh D et al.. Comparative In Vitro Evaluation of the Antimicrobial Efficacy of Tulsi, Triphala, and Aloe Vera against Streptococcus mutans Relative to Chlorhexidine.. Int J Clin Pediatr Dent. 2025. PMID:41552029.PMID 41552029 ↗Journal Int J Clin Pediatr DentYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41552029/
-
Observational / other LOW evidence YELLOWEfficacy of Emblica Officinalis and Curcumin Longa, Two Significant Herbal Antioxidants, in the Management of OSMF: A Comparative Cross-sectional Study. ↗Bhambal AM et al.. Efficacy of Emblica Officinalis and Curcumin Longa, Two Significant Herbal Antioxidants, in the Management of OSMF: A Comparative Cross-sectional Study.. J Pharm Bioallied Sci. 2025. PMID:41522910.PMID 41522910 ↗Journal J Pharm Bioallied SciYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41522910/
-
Observational / other LOW evidence YELLOWIn vitro assessment of anti-glioblastoma potential of Emblica officinalis methanolic fruit extract and green nanoparticles in U87-MG cells. ↗Chary KJS et al.. In vitro assessment of anti-glioblastoma potential of Emblica officinalis methanolic fruit extract and green nanoparticles in U87-MG cells.. Med Oncol. 2025. PMID:41085866.PMID 41085866 ↗Journal Med OncolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41085866/
-
Observational / other LOW evidence YELLOWDevelopment, Molecular Docking, and Anti-Anemia Potential of Polyherbal Formulation. ↗Bharati D et al.. Development, Molecular Docking, and Anti-Anemia Potential of Polyherbal Formulation.. Biology (Basel). 2025. PMID:40906412.PMID 40906412 ↗Journal Biology (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40906412/
-
Observational / other LOW evidence YELLOWMyocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity. ↗Tiwari DD et al.. Myocardial-salvaging Effects of a Novel Polyherbal Combination with Dipeptidyl Peptidase-4 Inhibitory Activity.. Niger Postgrad Med J. 2025. PMID:40745883.PMID 40745883 ↗Journal Niger Postgrad Med JYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/40745883/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Amla Fruit Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Amla Fruit Extract
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.